Serna-Candel C, López-Ibor L, Matías-Guiu J
Neurologia. 2010 Jun;25(5):273-8.
The evidence that recanalization and reperfusion of the distal vascular bed in appropriately selected patients is crucial to achieve good functional outcome has triggered interest and research into endovascular treatment of acute ischemic stroke.
Intravenous (iv) thrombolytic therapy is the treatment of choice in patients with acute ischemic stroke, however, it has certain limitations. Endovascular treatment is a promising alternative with theoretical advantages over iv therapy, such as an increased frequency of recanalization and longer therapeutic windows. Endovascular reperfusion strategies include intra-arterial fibrinolysis with drugs, or endovascular mechanical devices for thrombectomy or thrombus disruption, thromboaspiration, or thrombus entrapment in the vessel wall. The ideal of comprehensive treatment of acute stroke would provide specificity to treat an individual patient: with specific arterial occlusion and collaterals and a determined physiology of acute cerebral ischemia. With all this information, we would decide the best therapeutic strategy for the patient, and move from just a time-based approach to include a pathophysiology approach as well, and thus different patients could have different therapeutic windows. The endovascular treatment situation in Spain is heterogeneous and requires human and material resources to enable it to be implemented throughout the country.
Endovascular treatment of stroke is a new therapeutic tool for achieving reperfusion safely in patients ineligible for Alteplase or who have failed reperfusion with an iv fibrinolytic.
有证据表明,在适当选择的患者中实现远端血管床的再通和再灌注对于获得良好的功能结局至关重要,这引发了人们对急性缺血性卒中血管内治疗的兴趣和研究。
静脉溶栓治疗是急性缺血性卒中患者的首选治疗方法,然而,它有一定的局限性。血管内治疗是一种有前景的替代方法,理论上比静脉治疗更具优势,例如再通频率增加和治疗窗更长。血管内再灌注策略包括动脉内药物溶栓,或用于血栓切除术、血栓破碎、血栓抽吸或血管壁血栓捕获的血管内机械装置。急性卒中综合治疗的理想目标是为个体患者提供特异性治疗:针对特定的动脉闭塞、侧支循环以及确定的急性脑缺血生理状态。有了所有这些信息,我们就能为患者确定最佳治疗策略,从仅基于时间的方法转变为也包括病理生理学方法,这样不同患者可能有不同的治疗窗。西班牙的血管内治疗情况参差不齐,需要人力和物力资源才能在全国范围内实施。
卒中的血管内治疗是一种新的治疗工具,可安全地为不符合阿替普酶治疗条件或静脉溶栓再灌注失败的患者实现再灌注。